NCT06112275: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 4 taking part
- Started
- 28 Feb 2024
- Primary completion
- Sep 2030
- Arms
- Cohort A, Cohort B, Cohort C, Cohort D
- Results
- None posted
- 1 Nov 2023: Trial registered
- 28 Feb 2024: Trial started